Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fade Mahmoud

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 31, 2017
Could knee inflammatory synovitis be induced by pembrolizumab?Fade Mahmoud, John T Wilkinson, Alison Gizinski, et al.
The American Journal of Hospice & Palliative Care|September 12, 2009
Methylphenidate side effects in advanced cancer: a retrospective analysisWael Lasheen, Declan Walsh, Fade Mahmoud, et al.
Cancer Biology & Therapy|April 23, 2016
Role of EZH2 histone methyltrasferase in melanoma progression and metastasisFade Mahmoud, Bradley Shields, Issam Makhoul, et al.
Case Reports in Hematology|January 24, 2019
Thrombotic Thrombocytopenic Purpura due to Checkpoint InhibitorsAlexey Youssef, Nawara Kasso, Antonio Sergio Torloni, et al.
Palliative Medicine|November 14, 2009
The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer painWael Lasheen, Declan Walsh, Fade Mahmoud, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 20, 2017
Do checkpoint inhibitors rely on gut microbiota to fight cancer?Belal Firwana, Nathan Avaritt, Bradley Shields, et al.
The Permanente Journal|February 26, 2020
Immunotherapy Outcomes in Advanced Melanoma in Relation to AgeKrishna Joshi, Dinesh Atwal, Rahul Ravilla, et al.
Cancer Biology & Therapy|May 18, 2017
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattackFade Mahmoud, Bradley Shields, Issam Makhoul, et al.
Oncotargets and Therapy|November 10, 2018
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanomaSunilkumar Kakadia, Naveen Yarlagadda, Ramez Awad, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 26, 2015
Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literatureAl-Ola Abdallah, Aline Herlopian, Rahul Ravilla, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 31, 2017
Could knee inflammatory synovitis be induced by pembrolizumab?Fade Mahmoud, John T Wilkinson, Alison Gizinski, et al.
The American Journal of Hospice & Palliative Care|September 12, 2009
Methylphenidate side effects in advanced cancer: a retrospective analysisWael Lasheen, Declan Walsh, Fade Mahmoud, et al.
Cancer Biology & Therapy|April 23, 2016
Role of EZH2 histone methyltrasferase in melanoma progression and metastasisFade Mahmoud, Bradley Shields, Issam Makhoul, et al.
Case Reports in Hematology|January 24, 2019
Thrombotic Thrombocytopenic Purpura due to Checkpoint InhibitorsAlexey Youssef, Nawara Kasso, Antonio Sergio Torloni, et al.
Palliative Medicine|November 14, 2009
The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer painWael Lasheen, Declan Walsh, Fade Mahmoud, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 20, 2017
Do checkpoint inhibitors rely on gut microbiota to fight cancer?Belal Firwana, Nathan Avaritt, Bradley Shields, et al.
The Permanente Journal|February 26, 2020
Immunotherapy Outcomes in Advanced Melanoma in Relation to AgeKrishna Joshi, Dinesh Atwal, Rahul Ravilla, et al.
Cancer Biology & Therapy|May 18, 2017
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattackFade Mahmoud, Bradley Shields, Issam Makhoul, et al.
Oncotargets and Therapy|November 10, 2018
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanomaSunilkumar Kakadia, Naveen Yarlagadda, Ramez Awad, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 26, 2015
Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literatureAl-Ola Abdallah, Aline Herlopian, Rahul Ravilla, et al.
Pageof 4